Zydus Cadila

Purchase deal with firms only after Covid-19 vaccines prove effective: Centre

At present, vaccine candidates by Bharat Biotech, Serum Institute of India (Oxford University-AstraZeneca), and Zydus Cadila are under advanced stages of trials.

published on : 13th October 2020

If everything goes well India would get COVID-19 vaccine by year-end: Harsh Vardhan

Three COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India.

published on : 24th August 2020

COVID-19: Zydus Cadila launches least expensive version on Remdesivir in India

The drug will be made available across India through the group’s strong distribution chain reaching out to government and private hospitals treating Covid patients, announced Zydus.

published on : 13th August 2020

Zydus Cadila launches COVID-19 drug Remdesivir in India under brand name Remdac

Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.

published on : 13th August 2020

ICMR says two COVID-19 vaccines on phase 2 trial now but researchers differ

Principal Investigators involved in the vaccine trial said that it will take at least a month for the first phase of the trial to be completed.

published on : 4th August 2020

Seven Indian pharma players race to develop COVID-19 vaccine

Leading vaccine major Serum Institute of India has said that it is hoping to develop a COVID-19 vaccine by the year-end.

published on : 19th July 2020

Zydus Cadila gets USFDA nod to market generic tension headache tablets

The company has received final approval to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.

published on : 18th July 2020

Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate

In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.

published on : 15th July 2020

Zydus Cadila gets approval from Mexican authority to test COVID-19 drug Desidustat

The company said it will conduct a study to evaluate the efficacy and safety of Desidustat tablets for the management of COVID-19 patients.

published on : 6th July 2020

Scientists strike note of caution as 'Made in India' vaccine programme gains momentum

Phase 1 trials are small-scale, usually involving few participants, to assess whether the vaccine is safe for humans.

published on : 4th July 2020

After Covaxin, DCGI nod to human trials for potential Covid-19 vaccine by Zydus-Cadilla

ICMR DG Dr Balram Bhargava said that the subject enrollment should be completed by July 7 as the government is looking to launch the vaccine by August 15.

published on : 3rd July 2020
IPL_2020